EGFR-mutated NSCLC: A roadmap to treatment sequences.
Med
; 5(9): 1044-1047, 2024 Sep 13.
Article
en En
| MEDLINE
| ID: mdl-39276767
ABSTRACT
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the standard of care for the management of EGFR-mutated non-small cell lung cancer. Recent results from the HARMONi-A trial lead to considering ivonescimab-a first-in-class, bispecific antibody targeting PD-1 and VEGF-plus chemotherapy as a new second-line option following third-generation TKIs.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Carcinoma de Pulmón de Células no Pequeñas
/
Inhibidores de Proteínas Quinasas
/
Receptores ErbB
/
Neoplasias Pulmonares
/
Mutación
Límite:
Humans
Idioma:
En
Revista:
Med
Año:
2024
Tipo del documento:
Article
Pais de publicación:
Estados Unidos